BlackRock Amends Dexcom Stake: Passive Investment Update
Ticker: DXCM · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Dexcom stake, signaling a passive investment adjustment.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating a change in its ownership stake in Dexcom Inc. as of December 31, 2023. This filing, Amendment No. 6, shows BlackRock continues to hold a significant, though potentially adjusted, passive investment in Dexcom's Common Stock. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or strategy regarding Dexcom's future performance.
Why It Matters
Large institutional investors like BlackRock can influence stock prices and company direction, so changes in their holdings are closely watched by the market.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive investor and does not indicate any immediate or significant risk to the company or its stock.
Analyst Insight
Investors should note that BlackRock maintains a passive stake in Dexcom. While this filing doesn't reveal specific share count changes, it confirms BlackRock's continued interest. Smart investors might monitor future 13F filings for more detailed share count adjustments by BlackRock, as well as Dexcom's upcoming earnings reports for operational performance insights.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- DEXCOM INC (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 6 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 6)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as indicated under '(1)Names of reporting persons. BlackRock, Inc.' and in the 'FILED BY' section.
What is the subject company whose securities are being reported?
The subject company is DEXCOM INC, as stated under '(Name of Issuer) DEXCOM INC' and in the 'SUBJECT COMPANY' section.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified in the document under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed under Rule 13d-1(b), as indicated by the checked box '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding DEXCOM INC (DXCM).